1. QUESTION
===========

What is the optimal chemotherapy treatment for women with recurrent ovarian cancer who have previously received platinum-based chemotherapy?

2. CHOICE OF TOPIC AND RATIONALE
================================

In Canada, ovarian cancer is the fifth leading cause of cancer death among women and the leading cause of gynecologic cancer mortality [@b1-co14_5p195]. Estimates suggest that approximately 2400 new cases of ovarian cancer and 1550 deaths from the disease occurred in 2005, for a mortality-to-incidence ratio of 0.66 [@b1-co14_5p195].

Currently, standard primary therapy for advanced disease involves the combination of maximal cytoreductive surgery and chemotherapy with carboplatin plus paclitaxel or with carboplatin alone [@b2-co14_5p195],[@b3-co14_5p195]. Despite high initial response rates, a large proportion of patients relapse [@b4-co14_5p195], resulting in a therapeutic challenge. Because these patients are not curable [@b5-co14_5p195], the goal of therapy becomes improvement in both quality and length of life. The willingness of patients to undergo aggressive therapies for modest gains is growing, as has been documented for some other disease sites [@b6-co14_5p195]. This attitude has added a further dimension to the question of optimal treatment choice in this setting. The search has therefore been for active agents in women with recurrent disease after platinum-based chemotherapy.

One of the most frequently documented clinical surrogates for predicting response to chemotherapy in women with recurrent ovarian cancer has been the "platinum-free interval"---that is, the period of time from cessation of primary platinum-based chemotherapy to disease recurrence. Described in terms of platinum resistance or sensitivity, "responsiveness" is best characterized as a continuum. Increasing sensitivity to platinum is positively correlated with time from initial treatment to recurrence, such that disease that recurs more than 2 years after primary chemotherapy has a response rate to re-treatment with platinum approaching that associated with primary chemotherapy [@b7-co14_5p195].

Before a patient is treated with platinum-based chemotherapy, it is impossible to assess whether she will or will not be sensitive to platinum. In addition, cancer in individual patients becomes increasingly resistant to platinum over time. However, the rate at which resistance develops is variable, and thus some women respond to multiple lines of platinum-based chemotherapy and some respond not at all.

Women with platinum-resistant disease have uniformly low response rates to chemotherapy. Further complicating the decision of what to offer these patients is the wide range of approaches to treatment among specialists dealing with this dilemma. The options range from using less toxic treatments as therapy for symptomatic disease, including single-agent chemotherapy or best supportive care, to using a range of multi-agent regimens in aggressive therapy for asymptomatic patients.

Generally, the disease can be defined as "platinum-resistant" if recurrence is diagnosed less than 6 months after platinum-based chemotherapy has been completed. "Platinum-sensitive" disease can be defined as recurrence 6 months or more after the end of platinum-based chemotherapy. Although these definitions are somewhat arbitrary (because platinum sensitivity should be regarded more as a continuum), the decision to establish a 6-month cut-off for defining platinum resistance and sensitivity is supported by the outcomes from other studies of platinum-pre-treated patients with ovarian cancer [@b8-co14_5p195],[@b9-co14_5p195].

The present review of the evidence focuses on systemic chemotherapy; it does not evaluate intraperitoneal chemotherapy, hormonal therapy, or chemotherapy with bone marrow or stem-cell transplantation. The role of hormonal therapy in the treatment of recurrent ovarian cancer, although limited, is acknowledged to have been well addressed in published reviews [@b10-co14_5p195],[@b11-co14_5p195]. The present review summarizes the best available evidence on the optimal use of various chemotherapeutic agents in the treatment of platinum-sensitive and platinum-resistant recurrent ovarian cancer.

3. METHODS
==========

3.1 Guideline Development
-------------------------

The present systematic review of the evidence was developed by Cancer Care Ontario's Program in Evidence-Based Care ([pebc]{.smallcaps}) using the methods of the practice guidelines development cycle [@b12-co14_5p195]. Evidence was selected and extracted by one member of the [pebc]{.smallcaps}'s Gynecology Cancer Disease Site Group ([dsg]{.smallcaps}) and by a methodologist. All drafts of the text were reviewed, modified, and approved by the Gynecology Cancer [dsg]{.smallcaps}, and also by a Report Approval Panel ([rap]{.smallcaps}) of the [pebc]{.smallcaps}.

This review is a convenient and up-to-date source of the best available evidence on chemotherapy in the treatment of women with recurrent epithelial ovarian cancer. The body of evidence upon which the review is based primarily comprises data from randomized controlled trials ([rct]{.smallcaps}s). The systematic review and companion practice guideline developed by the Gynecology Cancer [dsg]{.smallcaps} are intended to promote evidence-based practice in Ontario, Canada. The [pebc]{.smallcaps} is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

An evidence summary on the management of women with recurrent ovarian cancer was originally completed in 2001 by the Gynecology Cancer [dsg]{.smallcaps} [@b13-co14_5p195]. The present document replaces the 2001 report.

3.2 Literature Search Strategy
------------------------------

The [medline]{.smallcaps} ([ovid]{.smallcaps}: 1966 through March 2006), [embase]{.smallcaps} ([ovid]{.smallcaps}: 1988 through March 2006), Cochrane Library ([ovid]{.smallcaps}: Issue 1, 2006), the Canadian Medical Association Infobase, and the National Guidelines Clearinghouse were systematically searched for evidence relevant to this report. In addition, the abstracts published in the proceedings of the meetings of the American Society of Clinical Oncology (1997--2005) and the European Society for Medical Oncology (2002, 2004) were similarly searched. Reference lists of related papers and recent review articles were scanned for additional citations.

Searches of electronic databases combined the terms (ovarian neoplasms/ or ovarian.ti. and neoplasm:.mp. or cancer.mp.) with (neoplasm recurrence local/ or neoplasm metastasis/ or recurren:.mp. or relapse:.mp. or resistance.mp.) and (drug therapy/ or antineoplastic agents/ or chemotherapy.mp.) for these study designs: [rct]{.smallcaps}s, meta-analyses, practice guidelines, and systematic reviews.

3.3 Study Selection Criteria
----------------------------

Articles were selected for inclusion in this systematic review of the evidence if they were [rct]{.smallcaps}s that compared chemotherapeutic agents as part of second- or greater-line treatment for patients with recurrent epithelial ovarian cancer who had previously been treated with platinum-containing chemotherapy, and if they reported data on at least one of the following outcomes of interest: overall survival, progression-free survival, tumour response rate, adverse events, or quality of life ([qol]{.smallcaps}).

Practice guidelines, meta-analyses, or systematic reviews explicitly based on randomized trials related to the guideline question were also eligible for inclusion in the systematic review of the evidence.

Articles were excluded from the systematic review of the evidence if they were written in a language other than English or if they included the use of intraperitoneal chemotherapy, hormonal therapy, or chemotherapy with bone marrow or stem-cell transplantation.

4. RESULTS
==========

4.1 Literature Search Results
-----------------------------

Thirteen randomized trials comparing various chemotherapy regimens for women with recurrent ovarian cancer were identified and deemed eligible for inclusion in the systematic review of the evidence [@b14-co14_5p195]--[@b26-co14_5p195]. In the event of multiple publications per trial, only the most recent publication was cited. Ten trials were fully published [@b14-co14_5p195]--[@b18-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195]--[@b24-co14_5p195],[@b26-co14_5p195], and three trials were reported as abstracts from conference proceedings [@b19-co14_5p195],[@b21-co14_5p195],[@b25-co14_5p195]. [Table I](#tI-co14_5p195){ref-type="table"} presents the literature search results and select trial characteristics.

4.2 Trial Characteristics
-------------------------

To be eligible to participate in the randomized trials, patients had to have recurrent ovarian cancer after prior first-line [@b14-co14_5p195],[@b16-co14_5p195]--[@b18-co14_5p195],[@b21-co14_5p195]--[@b23-co14_5p195],[@b25-co14_5p195],[@b26-co14_5p195] or prior first- or second-line treatment [@b15-co14_5p195],[@b19-co14_5p195],[@b20-co14_5p195],[@b24-co14_5p195] with platinum-containing chemotherapy. Where reported, patients were stratified by age [@b18-co14_5p195],[@b20-co14_5p195], presence of ascites [@b18-co14_5p195], type of prior chemotherapy [@b14-co14_5p195],[@b20-co14_5p195], chemotherapy-free interval [@b20-co14_5p195],[@b24-co14_5p195], number of lines of treatment [@b20-co14_5p195],[@b24-co14_5p195], bi-dimensionally measurable disease [@b14-co14_5p195], performance status [@b20-co14_5p195],[@b24-co14_5p195], platinum-free interval [@b14-co14_5p195],[@b16-co14_5p195]--[@b18-co14_5p195],[@b20-co14_5p195],[@b21-co14_5p195], presence of bulky disease exceeding 5 cm [@b17-co14_5p195],[@b21-co14_5p195], or treatment center [@b16-co14_5p195],[@b20-co14_5p195],[@b24-co14_5p195].

The median age of the patients ranged from a low of 54 years to a high of 61 years [@b14-co14_5p195]--[@b18-co14_5p195],[@b20-co14_5p195]--[@b24-co14_5p195]. Eight trials included patients over the age of 70 years [@b14-co14_5p195]--[@b18-co14_5p195], [@b21-co14_5p195],[@b23-co14_5p195],[@b24-co14_5p195], and four trials included patients who were more than 80 years of age [@b14-co14_5p195],[@b17-co14_5p195],[@b18-co14_5p195],[@b24-co14_5p195]. With the exception of one trial [@b18-co14_5p195], information on patient height, weight, body mass index, or menopausal status was not reported. In the one trial that reported those data [@b18-co14_5p195], the mean weight of the patients was approximately 66 kg, and the mean body surface was 1.7 m^2^.

As can be seen in Table I, various chemotherapeutic regimens were investigated across the thirteen trials. Carboplatin, paclitaxel, and topotecan were the most commonly used agents, however only two of the thirteen trials compared similar regimens: single-agent carboplatin versus combination carboplatin and paclitaxel [@b15-co14_5p195],[@b20-co14_5p195]. In the larger of the latter two trials [@b20-co14_5p195], 196 patients (24%) received chemotherapy other than carboplatin alone or the combination of carboplatin and paclitaxel.

Treatment schedules varied across the trials, with the scheduled cycles of chemotherapy ranging from a low of 4 to a high of 12 [@b14-co14_5p195]--[@b18-co14_5p195],[@b20-co14_5p195]--[@b26-co14_5p195]. One trial did not report information about cycles [@b19-co14_5p195], and in one trial [@b24-co14_5p195], treatment was intended to continue until progression, undue toxicity, or patient refusal.

In eight trials [@b14-co14_5p195]--[@b16-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195],[@b25-co14_5p195],[@b26-co14_5p195], patients were randomized to either single-agent or multi-agent chemotherapy, and in five randomized trials, single-agent chemotherapy was compared with other single-agent chemotherapy [@b17-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195].

In five trials, only patients who responded for more than 6 months [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195] after first-line treatment with a platinum-containing regimen (considered "platinum-sensitive") were eligible to participate in the randomized studies. In four of those trials, platinum sensitivity was demonstrated beyond a 12-month period in approximately 60% [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195] or 100% [@b22-co14_5p195] of patients. In the remaining study, data on the persistence of platinum-sensitivity were not reported [@b23-co14_5p195]. In four of the five trials, second- or third-line treatment contained further platinum-containing chemotherapy; the one exception was a small study in which paclitaxel was used in one of the treatment arms [@b22-co14_5p195].

In eight studies [@b16-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195],[@b23-co14_5p195],[@b24-co14_5p195],[@b25-co14_5p195], 35%--100% of patients experienced progression less than 6 months after treatment with a platinum-containing regimen. Those patients were considered platinum-refractory or platinum-resistant. In seven of these eight studies of partial [@b16-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195],[@b25-co14_5p195] or complete platinum-resistance [@b26-co14_5p195], non-platinum-containing regimens were investigated. Again, the one exception was one small study in which oxaliplatin was used in one of the treatment arms [@b24-co14_5p195].

In five of the trials that included patients with both platinum-sensitive and platinum-resistant disease [@b16-co14_5p195]--[@b18-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195], results were also reported separately for the two subgroups of patients.

Protocols for treatment modification included cycle delay [@b15-co14_5p195]--[@b17-co14_5p195],[@b22-co14_5p195]--[@b24-co14_5p195], dose reduction [@b15-co14_5p195]--[@b18-co14_5p195],[@b23-co14_5p195],[@b24-co14_5p195],[@b26-co14_5p195], and use of erythropoietin [@b14-co14_5p195] or granulocyte colony--stimulating factor [@b14-co14_5p195],[@b17-co14_5p195],[@b18-co14_5p195],[@b23-co14_5p195],[@b26-co14_5p195]. Where reported, patients were removed from the study if treatment delay was greater than 2 [@b18-co14_5p195] or 6 weeks [@b15-co14_5p195], if adverse events occurred [@b15-co14_5p195],[@b17-co14_5p195], [@b18-co14_5p195],[@b24-co14_5p195], or if dose reductions fell below the minimum allowable dose [@b24-co14_5p195]. Patient crossover to the alternative agent, considered third-line chemotherapy, was allowed in two trials [@b18-co14_5p195],[@b22-co14_5p195] and was not reported in the remaining trials [@b14-co14_5p195]--[@b17-co14_5p195],[@b19-co14_5p195]--[@b21-co14_5p195],[@b23-co14_5p195]--[@b26-co14_5p195].

The primary study endpoints were reported to be various combinations of response rate [@b15-co14_5p195],[@b18-co14_5p195],[@b23-co14_5p195]--[@b26-co14_5p195], duration of response [@b18-co14_5p195], progression-free survival [@b14-co14_5p195],[@b17-co14_5p195], [@b18-co14_5p195],[@b21-co14_5p195], toxicity [@b23-co14_5p195], and overall survival [@b16-co14_5p195],[@b17-co14_5p195],[@b19-co14_5p195]--[@b22-co14_5p195].

Seven trials reported [qol]{.smallcaps} as a study endpoint [@b14-co14_5p195],[@b15-co14_5p195],[@b17-co14_5p195]--[@b20-co14_5p195],[@b24-co14_5p195]. Assessment of [qol]{.smallcaps} used the European Organization for Research on Cancer treatment [qol]{.smallcaps} questionnaire [@b14-co14_5p195],[@b15-co14_5p195],[@b17-co14_5p195],[@b18-co14_5p195],[@b20-co14_5p195],[@b24-co14_5p195], including the ovarian cancer module [@b14-co14_5p195], and a "specific checklist" that was not fully described [@b24-co14_5p195]. One trial reported as an abstract did not provide details on [qol]{.smallcaps} assessment or on [qol]{.smallcaps} results between treatment groups [@b19-co14_5p195]. The remaining trials did not report whether data on [qol]{.smallcaps} were collected [@b16-co14_5p195],[@b21-co14_5p195]--[@b23-co14_5p195],[@b25-co14_5p195],[@b26-co14_5p195].

Overall, in assessing the characteristics of the thirteen randomized trials, it was clear that the eligible trials varied widely, making it difficult to compare results across trials. Important differences in platinum sensitivity, type of chemotherapy, number of agents employed, cycles of chemotherapy, and study endpoints all contributed to inter-trial heterogeneity.

4.3 Trial Quality
-----------------

The identified trials were non-blinded multi-centre [@b14-co14_5p195],[@b16-co14_5p195]--[@b26-co14_5p195] or single-centre [@b15-co14_5p195] phase [iii]{.smallcaps} [@b14-co14_5p195],[@b16-co14_5p195]--[@b21-co14_5p195],[@b23-co14_5p195],[@b25-co14_5p195],[@b26-co14_5p195] or phase [ii rct]{.smallcaps}s [@b15-co14_5p195],[@b22-co14_5p195],[@b24-co14_5p195]. In seven trials, the randomization procedure was reported [@b15-co14_5p195],[@b16-co14_5p195],[@b18-co14_5p195],[@b20-co14_5p195],[@b23-co14_5p195],[@b24-co14_5p195],[@b26-co14_5p195]; the remaining trials did not report that information [@b14-co14_5p195],[@b17-co14_5p195],[@b19-co14_5p195],[@b21-co14_5p195],[@b22-co14_5p195],[@b25-co14_5p195]. Eight trials reported patient accrual with sufficient power to detect significant differences between treatment groups [@b14-co14_5p195]--[@b17-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195],[@b26-co14_5p195] at an alpha level of 0.05 [@b15-co14_5p195],[@b16-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195],[@b26-co14_5p195]. Five trials did not report information on power calculations [@b18-co14_5p195],[@b19-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195],[@b25-co14_5p195]. One phase [ii]{.smallcaps} trial employed a "pick the winner design" that was sufficiently powered; however, given the small number of patients involved, a formal statistical comparison between treatment arms was not planned. That trial eventually reported statistical comparisons of primary and secondary endpoints as part of exploratory analyses [@b15-co14_5p195].

Baseline characteristics were reported or observed to be generally similar across treatment groups in twelve trials [@b14-co14_5p195]--[@b24-co14_5p195],[@b26-co14_5p195]; they were not reported in one trial [@b25-co14_5p195]. Statistical comparisons between baseline characteristics of the patients were reported in two trials, with no statistically significant differences being detected between treatment groups [@b15-co14_5p195],[@b21-co14_5p195].

Across eleven trials, completeness of follow-up was reported or inferred to be greater than 80% [@b14-co14_5p195]--[@b18-co14_5p195], [@b20-co14_5p195]--[@b24-co14_5p195],[@b26-co14_5p195], and in two trials data on follow-up were not available [@b19-co14_5p195],[@b25-co14_5p195]. Eight trials reported data using the intent-to-treat principle [@b15-co14_5p195]--[@b18-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195],[@b26-co14_5p195]. In three trials [@b14-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195] where intent-to-treat information was not explicitly reported, it could be inferred from the published trial data.

In general, the methodologic quality of the trials---that is, their internal validity---was deemed to be sufficient to permit meaningful conclusions to be drawn from the results of the individual trials (external validity).

4.4 Outcomes
------------

[Table II](#tII-co14_5p195){ref-type="table"} shows response and survival results for the thirteen randomized trials identified in the review of the evidence.

### 4.4.1 Survival

Survival data were reported [@b14-co14_5p195]--[@b22-co14_5p195],[@b24-co14_5p195],[@b25-co14_5p195] or extracted from survival curves [@b23-co14_5p195],[@b26-co14_5p195] for all of the randomized trials. Survival was reported to be a primary study endpoint in six of the thirteen trials [@b16-co14_5p195],[@b17-co14_5p195],[@b19-co14_5p195]--[@b22-co14_5p195].

As [Table II](#tII-co14_5p195){ref-type="table"} shows, four trials detected significant differences in survival between treatment groups [@b15-co14_5p195],[@b17-co14_5p195], [@b20-co14_5p195],[@b22-co14_5p195]. In three trials of these trials (with 100% of the patients being platinum-sensitive), significant survival advantages were detected with combination platinum-containing chemotherapy as compared with single-agent chemotherapy [@b15-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195]. In the remaining trial (with a mixed platinum-sensitive and platinum-resistant patient population) [@b17-co14_5p195], a statistically significant median survival advantage of 2 months was detected with liposomal doxorubicin as compared with topotecan. In that trial, no significant differences were observed in response rate or progression-free survival, and the survival curves for the treatment arms were virtually indistinguishable for approximately the first year. Shortly beyond year 1, the survival curve for liposomal doxorubicin began to show a survival benefit [@b17-co14_5p195]. That result could indicate that an unexplained treatment effect occurred after disease progression. One possibility is that, because liposomal doxorubicin was available only on study at the time, treatment crossover upon progression was not possible for patients in the topotecan treatment arm, but that patients in the liposomal doxorubicin arm probably would have received subsequent topotecan. The sequence of the chemotherapy delivery may perhaps account for the treatment effect; however, with limited clinical benefit and no follow-up data reported, the Gynecology Cancer [dsg]{.smallcaps} concluded that further confirmation of the observed results would be needed to support the superiority of one agent over another in that trial. No other survival differences were reported in the remaining nine trials [@b14-co14_5p195],[@b16-co14_5p195],[@b18-co14_5p195],[@b19-co14_5p195],[@b21-co14_5p195],[@b23-co14_5p195]--[@b26-co14_5p195].

Five trials reported separate subgroup analyses of survival results by platinum sensitivity [@b16-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195]. In the platinum-sensitive subgroups, three trials [@b16-co14_5p195],[@b18-co14_5p195],[@b21-co14_5p195] reported no significant survival difference between treatment groups; one trial [@b17-co14_5p195] detected a survival advantage with liposomal doxorubicin; and one trial [@b19-co14_5p195] detected a survival advantage with topotecan. Gordon *et al.* [@b17-co14_5p195] reported a significant survival advantage for pegylated doxorubicin over topotecan (27 months vs. 18 months, *p* = 0.017). That 9-month survival benefit seems promising, but it is based on a subgroup analysis and, again, the Gynecology Cancer [dsg]{.smallcaps} concluded that further confirmation of those results would be needed to establish the superiority of liposomal doxorubicin over topotecan. In the trial reported by Meier *et al.* [@b19-co14_5p195], topotecan was more effective than treosulphan for patients with platinum-sensitive disease (16 months vs. 14 months, *p* = 0.0068).

For patients with platinum-refractory or platinum-resistant disease, none of the trials detected any statistically significant survival advantage with one chemotherapy agent over another.

### 4.4.2 Progression-Free Survival

Progression-free survival was reported in eleven of the thirteen randomized trials [@b14-co14_5p195]--[@b22-co14_5p195],[@b24-co14_5p195],[@b25-co14_5p195] and was extracted from survival curves in one trial [@b23-co14_5p195]. The remaining trial reported median duration of response as a primary outcome of interest [@b26-co14_5p195]. Progression-free survival was reported to be the primary study endpoint in four of the thirteen randomized trials [@b14-co14_5p195],[@b17-co14_5p195],[@b18-co14_5p195],[@b21-co14_5p195].

In four trials of 100% platinum-sensitive patients, a significant survival advantage was detected with combination platinum-containing chemotherapy as compared with single-agent chemotherapy with carboplatin [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195] or paclitaxel [@b22-co14_5p195]. In one trial of non-platinum-containing chemotherapy [@b19-co14_5p195], topotecan was superior to treosulphan by a span of approximately 2 months (5.4 months vs. 3.0 months, *p* \< 0.001). No other statistically significant differences in progression-free survival or in median duration of response [@b26-co14_5p195] were reported in the remaining trials [@b16-co14_5p195]--[@b18-co14_5p195],[@b21-co14_5p195],[@b24-co14_5p195]--[@b26-co14_5p195].

Five trials reported subgroup analyses for progression-free survival by patient sensitivity status [@b16-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195]. Gordon *et al.* [@b17-co14_5p195] reported a significant advantage in progression-free survival with pegylated doxorubicin over topotecan for patients with platinum-sensitive disease (6.7 months vs. 5.4 months, *p* = 0.037), but not for patients with platinum-resistant disease. In the trial reported by Meier *et al.* [@b19-co14_5p195], topotecan was more effective than treosulphan for patients both with platinum-sensitive disease (6.6 months vs. 5.2 months, *p* = 0.0179) and with platinum-resistant disease (4.2 months vs. 2.2 months, *p* = 0.0279). In the two foregoing trials, the clinical benefit of the superior treatment did not exceed 2 months. In the remaining three trials [@b16-co14_5p195],[@b18-co14_5p195],[@b21-co14_5p195], no significant differences were detected between treatment subgroups.

### 4.4.3 Tumour Response

Tumour response was reported to be a primary study endpoint in six of the randomized trials [@b15-co14_5p195],[@b18-co14_5p195],[@b23-co14_5p195]--[@b26-co14_5p195]. Two of these randomized trials detected statistically significant differences in overall response rate favouring carboplatin-based combination chemotherapy over single-agent carboplatin [@b14-co14_5p195],[@b15-co14_5p195]. The remaining trials reported no significant differences in response rate between treatment groups [@b16-co14_5p195]--[@b26-co14_5p195].

4.5 Adverse Events Associated with Chemotherapy
-----------------------------------------------

As [Table III](#tIII-co14_5p195){ref-type="table"} shows, data on adverse events varied with the treatment regimen, and although reporting differed between the studies, adverse events correlated with known toxicity profiles.

Ten trials reported statistically significant differences in adverse events by treatment group [@b14-co14_5p195]--[@b18-co14_5p195], [@b21-co14_5p195]--[@b23-co14_5p195],[@b25-co14_5p195],[@b26-co14_5p195]. On average, severe adverse events, generally hematologic, were significantly associated with combination chemotherapy in trials comparing a combination regimen with single-agent chemotherapy.

The agents most commonly used were paclitaxel, carboplatin, topotecan, and pegylated doxorubicin. Adverse events associated with paclitaxel included alopecia (any grade) in 62%--100% of patients, neurotoxic effects (any grade) in 5%--42% of patients, severe leucopenia in 4%--24% of patients, and severe nausea and vomiting in 2%--6% of patients [@b16-co14_5p195],[@b18-co14_5p195],[@b21-co14_5p195]--[@b22-co14_5p195],[@b24-co14_5p195]--[@b26-co14_5p195]. Carboplatin was associated with low rates of severe hematologic events (typically 15% of patients or fewer), severe nausea and vomiting in approximately 10% of patients or fewer, and any grade of alopecia in 2%--25% of patients [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195],[@b23-co14_5p195]. When compared with paclitaxel or pegylated doxorubicin, topotecan was significantly associated with increased severe hematologic toxicities, and some grade of alopecia occurred in 49%--76% of patients [@b17-co14_5p195],[@b18-co14_5p195]. In the two trials that studied pegylated doxorubicin, the adverse events associated with that agent included any grade of palmar--plantar erythrodysesthesia (PPE) in approximately one half of patients and severe PPE in 23% (Gordon *et al.* [@b17-co14_5p195]) and 16% (O'Byrne *et al.* [@b21-co14_5p195]) of patients. One trial [@b21-co14_5p195] also reported a significant difference in severe stomatitis in patients treated with pegylated doxorubicin as compared with those treated with paclitaxel (10% vs. 1%, *p* = 0.03).

4.6 Quality of Life
-------------------

Six trials reported data on [qol]{.smallcaps} outcomes [@b14-co14_5p195],[@b15-co14_5p195],[@b17-co14_5p195],[@b18-co14_5p195],[@b20-co14_5p195],[@b24-co14_5p195]. Overall, no statistically significant differences in [qol]{.smallcaps} outcome were detected between treatment groups in any of these randomized trials.

Three trials reported results of subgroup analyses on specific [qol]{.smallcaps} outcomes [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195]. One trial [@b14-co14_5p195] reported that symptomatic patients who received gemcitabine and carboplatin had improved global [qol]{.smallcaps}, including faster palliation of abdominal symptoms, than did patients treated with carboplatin alone. Another trial [@b15-co14_5p195], which reported very high (\>85%) non-compliance with questionnaire completion at 6 and 12 months, reported that the nausea and vomiting subscale scores were significantly higher (*p* = 0.033) with carboplatin than with the combination of carboplatin and paclitaxel. In the [icon]{.smallcaps}4 trial [@b20-co14_5p195], the authors reported that, when the nausea and vomiting subscale was analyzed separately, [qol]{.smallcaps} on that subscale was significantly worse among women receiving single-agent chemotherapy than it was in women receiving multiple-agent chemotherapy (*p* = 0.0014).

5. DISCUSSION
=============

The goals of therapy for patients with recurrent ovarian cancer are to improve [qol]{.smallcaps} and extend survival. Therefore, with regard to deriving conclusions based on the available evidence, it was important to consider the generalizability of the results, to assess the methodologic quality of the studies forming the evidentiary base, and to interpret the results in a clinically meaningful manner.

Even though the literature search uncovered thirteen [rct]{.smallcaps}s that investigated the role of chemotherapy in patients with recurrent ovarian cancer and prior platinum exposure, the data are incomplete. Although platinum sensitivity status is more of a continuum than a discrete event, it has an impact on patient outcomes---an impact supported by the current body of evidence. Only six of the thirteen trials included solely patients who were considered either 100% platinum-sensitive [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195],[@b23-co14_5p195] or 100% platinum-resistant [@b26-co14_5p195]. A further five trials reported subgroup analyses by platinum sensitivity [@b16-co14_5p195]--[@b19-co14_5p195],[@b21-co14_5p195], but those studies were not designed to compare differences between subgroups, and their results must therefore be interpreted with caution.

In addition, study size, characteristics, and design must also be considered when interpreting the data. Eight trials provided power calculations, but four trials randomized fewer than 50 patients per arm; five trials included approximately 100 patients per arm; and the four larger studies randomized at least 150 patients per arm. Unsurprisingly, most of statistically significant results stemmed from the larger randomized trials. The characteristics of the trials varied widely, exhibiting important differences in chemotherapy regimens such as platinum versus non-platinum-containing regimens, single-agent versus combination chemotherapy, and varying lengths in the planned chemotherapy cycles, making it difficult to compare results across trials. In addition, the primary study endpoints also varied widely across the trials. These endpoints were roughly divided by response rate [@b15-co14_5p195],[@b18-co14_5p195],[@b23-co14_5p195]--[@b26-co14_5p195], progression-free survival [@b14-co14_5p195],[@b17-co14_5p195], [@b18-co14_5p195],[@b21-co14_5p195], and overall survival [@b16-co14_5p195],[@b17-co14_5p195],[@b19-co14_5p195]--[@b22-co14_5p195].

Despite the noted differences among the identified trials, the methodologic quality of the individual trials was reasonably high, with most trials reporting (but not statistically comparing) well-balanced baseline patient characteristics, completeness of follow-up greater than 80%, power and patient accrual sufficient to detect statistically significant differences between treatment groups, and the intent-to-treat principle. These trials were generally multicentric investigations that took place in the phase [iii]{.smallcaps} setting.

Overall, for patients with platinum-sensitive recurrent disease, evidence from four trials [@b14-co14_5p195],[@b15-co14_5p195],[@b20-co14_5p195],[@b22-co14_5p195] is sufficient to conclude that platinum-containing combination chemotherapy improves response and survival outcomes as compared with single-agent carboplatin or paclitaxel. The more compelling evidence comes from one large trial [@b20-co14_5p195] and one small supporting trial [@b15-co14_5p195] that compared the combination of carboplatin and paclitaxel with single-agent carboplatin. The combination of gemcitabine and carboplatin also improved response and progression-free survival as compared with carboplatin alone [@b14-co14_5p195]. In the single-agent setting, carboplatin was not as efficacious as combination chemotherapy, but it still showed consistent efficacy across trials with a manageable toxicity profile. As part of non-platinum-containing chemotherapy, paclitaxel, topotecan, and liposomal doxorubicin showed activity in patients with platinum-sensitive disease [@b17-co14_5p195],[@b18-co14_5p195],[@b21-co14_5p195]; however, none of those agents has been compared in the randomized setting against platinum-based chemotherapy. In that setting, given the unexpected findings, subgroup analyses, and mixed results across trials, establishing the superiority of one non-platinum agent over another is difficult without further confirmation of results.

For patients with platinum-refractory or -resistant disease, the non-platinum-containing combination chemotherapy in three trials was no more efficacious than was the non-platinum single-agent chemotherapy; however, in terms of the number of trials, number of patients studied, and number of regimens investigated, the data are limited.

In five trials, non-platinum single-agent treatment options included paclitaxel, topotecan, liposomal doxorubicin, or treosulphan. One trial [@b17-co14_5p195] reported a 2-month statistically significant difference in median survival with liposomal doxorubicin in a mixed platinum-sensitive patient population; however, the limited clinical benefit, coupled with unexpected findings, subgroup analyses, and a lack of confirmation of results leads to a conclusion of uncertain superiority for the agents being compared. On the basis of one trial [@b19-co14_5p195], topotecan appears to be more effective than treosulphan in extending progression-free survival, but that result does little to inform the clinical scenario in the context of current clinical practice. It should be noted that the survival benefit of any one chemotherapy agent over another did not exceed 3 months in any of the randomized trials.

Thus, for patients with platinum-refractory or -resistant disease, the data provide little definitive comment on the efficacy of combination chemotherapy as compared with single-agent chemotherapy or on the efficacy of any single agent over another.

6. CONCLUSIONS
==============

Given the available data, it would seem reasonable to conclude that, as long as patients continue to respond to platinum-based chemotherapy with no contraindications, then combination platinum-based chemotherapy should be considered for this patient population. This conclusion is based on the improved survival benefits, but recognizes the increase in adverse events.

If combination therapy is not indicated (because of toxicity or otherwise), then a single platinum agent should be considered if indicated. Single-agent carboplatin has been effective in this patient population, and it has a manageable toxicity profile. Patients could continue to receive platinum-based chemotherapy across multiple lines, if need be, for as long as they remain sensitive to platinum-containing chemotherapy.

If platinum-containing chemotherapy is not being considered, then monotherapy with a non-platinum agent should be considered on the basis of patient preference, toxicity profile, ease of administration, and availability. Single-agent paclitaxel, topotecan, or pegylated liposomal doxorubicin have demonstrated activity in this patient population and are reasonable treatment options.

For patients who do not respond to platinum-based chemotherapy, then treatment decisions should be based on patient preference, toxicity profile, ease of administration, and availability. The use of combination chemotherapy does not appear to be advantageous in this group of patients, and no evidence either supports or refutes the use of multiple lines of chemotherapy in patients with platinum-resistant recurrences. Single-agent paclitaxel, topotecan, or pegylated liposomal doxorubicin have demonstrated activity in this patient population and are reasonable treatment options.

Platinum-sensitivity status in these patients should be regarded as a continuum rather than a discrete outcome. It is therefore recognized that each patient needs to be individually assessed to determine optimal therapy in terms of recurrence, sensitivity to platinum, toxicity, ease of administration, and patient preference. Participation in randomized trials should be encouraged for all patients, where appropriate.

Further research from randomized trials is needed to determine the optimum chemotherapeutic regimen for patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer. The roles of further cytoreductive surgery and carboplatin desensitizing agents remain to be determined. Currently, studies planned or underway include the Southwest Oncology Group S0200 phase [iii]{.smallcaps} trial of carboplatin with or without pegylated doxorubicin in platinum-sensitive disease, the [calypso]{.smallcaps} study (a Gynaecologic Cancer Intergroup study) of carboplatin and paclitaxel versus carboplatin and liposomal doxorubicin in platinum-sensitive recurrence, and another Intergroup study ([icon]{.smallcaps}6, led by the U.K. Medical Research Council) in patients with platinum-sensitive disease, which will explore the addition of a targeted molecular agent (AZD2171, against vascular endothelial growth factor) to carboplatin and paclitaxel therapy. The results of ongoing trials should help to determine the most appropriate treatment options for patients with recurrent epithelial ovarian cancer.

7. INTERNAL REVIEW OF THE PRACTICE GUIDELINE REPORT
===================================================

7.1 RAP Feedback
----------------

Before external review, the draft report was reviewed by the [pebc rap]{.smallcaps}, which consists of 2 members, including an oncologist with expertise in clinical and methodology issues.

One major issue raised by the [rap]{.smallcaps} was that the link between the evidence and the recommendations for platinum-resistant or -refractory patients was confusing to follow. The [rap]{.smallcaps} commented that although two trials appeared to show differences in survival, the relevant information did not appear to factor into the formulation of the practice recommendation. Related to this issue was the comment that greater discussion was required concerning the [dsg]{.smallcaps}'s interpretation of results from one trial in which methodologic issues were raised about the crossing of survival curves, but in which was also detected a significant survival difference between treatment groups. The [rap]{.smallcaps} commented that the [dsg]{.smallcaps} had not adequately justified its statement regarding the methodologic concerns potentially affecting the survival outcomes in that trial.

As part of minor comments, suggestions about the structure and format of the report were also offered. The [rap]{.smallcaps} found that the text-dense format of the Trial Characteristics and Trial Quality sections made it difficult for readers to link the various elements and to interpret the findings in a meaningful manner. One [rap]{.smallcaps} member felt that use of subheadings could be helpful, and one suggested that the information might be better presented in tables.

As a final comment, the [rap]{.smallcaps} noted that a reference in the Introduction to the case fatality ratio was unclear about whether that value came from a separate reference or was calculated from the incidence and mortality data presented in the same sentence. The [rap]{.smallcaps} suggested that the [dsg]{.smallcaps} reword or clarify.

7.2 Modifications
-----------------

In response to the [rap]{.smallcaps}'s comments, the Gynecology Cancer [dsg]{.smallcaps} addressed the presentation of the link between the evidence and the recommendations in the Survival, Discussion, and Key Evidence sections. The primary issue was that results from the trial by Gordon *et al.,* which detected an overall 2-month survival benefit with pegylated doxorubicin over topotecan was not reflected in the recommendations where liposomal doxorubicin, topotecan, and paclitaxel were all listed as reasonable treatment options. The findings from that trial were unexpected, because no significant differences in response rate or progression-free survival had been detected between the treatment arms, and the survival curves for the treatment arms were virtually indistinguishable for approximately the first year. The trial then went on to show a 2-month survival benefit shortly beyond year 1 that was even more pronounced in the subgroup analysis of platinum-sensitive patients (9-month improvement in median survival).

The Survival section hypothesized that a treatment effect may have occurred after disease progression, one possibility being that, because liposomal doxorubicin was available only on study at the time, treatment crossover upon progression was not possible for patients in the topotecan treatment arm, but patients in the liposomal doxorubicin arm were likely to have received subsequent topotecan. Perhaps the sequence of the chemotherapy delivery can account for the treatment effect. However, with the unexpected findings, the limited clinical benefit outside of subgroup analysis, and no follow-up data reported, that trial would need further confirmation of results before the Gynecology Cancer [dsg]{.smallcaps} could conclude superiority of one agent over another.

In the second trial in which the superiority of topotecan over treosulphan in progression-free survival was detected, the results from that trial did little to inform the clinical picture, given that treosulphan was not being recommended as one of the three single agents being considered as reasonable treatment options. Potentially confusing subgroup results from that trial were removed from [Table II](#tII-co14_5p195){ref-type="table"}, and the description of the results was revised to improved clarity.

To improve clarity in the Results section, summary sentences were added to the Trial Characteristics and Trial Quality subsections: one sentence provides an overall assessment of the relative homogeneity or heterogeneity of the identified trials, and the other comments on external validity through an assessment of the internal validity of the trials. The text in these sections was also divided into smaller paragraphs to improve readability.

Finally, where the Introduction referred to the potentially confusing case fatality ratio, the wording was changed to a ratio of mortality to incidence.

8. EXTERNAL REVIEW OF THE PRACTICE GUIDELINE REPORT
===================================================

8.1 Practitioner Feedback Survey
--------------------------------

The systematic review and practice guideline were distributed for review and feedback to practitioners throughout Ontario, Canada, in accordance with the practice guidelines development cycle [@b12-co14_5p195]. A sample of 170 practitioners in Ontario received the survey, which consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and of questions about whether the draft recommendations should be approved as a practice guideline. Written comments were invited. The practitioner feedback survey was mailed on September 18, 2006, and a complete repeat mailing was sent thereafter. The Gynecology Cancer [dsg]{.smallcaps} reviewed the results of the survey.

8.2 Survey Results
------------------

From among the 170 surveys sent, 85 responses were received. Responses include returned completed surveys, plus telephone, fax, and e-mail responses. Of the practitioners who responded, 22 indicated that the report was relevant to their clinical practice, and they completed the survey. [Table IV](#tIV-co14_5p195){ref-type="table"} summarizes key results.

Of the respondents, 7 provided written comments. In general, the comments were highly positive and accorded with the conclusions derived by the Gynecology Cancer [dsg]{.smallcaps}. Five practitioners commented favourably on the quality and development of the series overall, although one practitioner asked why the [dsg]{.smallcaps} would undertake a guideline given the level of evidence available for analysis. One practitioner commented that highly motivated patients with platinum-resistant disease often receive more than one line of chemotherapy. One practitioner suggested that a comment be added about treatment in platinum-sensitive patients after third-line chemotherapy. Two practitioners commented that addressing related topics such as carboplatin desensitization or further cytoreductive surgery would be helpful.

8.3 Action Taken
----------------

On the basis of the survey results, which were supportive of the guideline, the Gynecology Cancer [dsg]{.smallcaps} concluded that no substantive revisions to the document were needed.

The comment regarding the body of evidence in this treatment setting makes a valid point. However, the Gynecology Cancer [dsg]{.smallcaps} agreed that that it was possible and necessary to derive meaningful conclusions from the available randomized evidence. The need for further research on this topic area is well recognized. The authors also recognize that the ideal number of regimens is not well informed by the evidence, but strategies for the management of recurrent ovarian cancer is the focus of another guideline in development by the Gynecology Cancer [dsg]{.smallcaps}. The impact of related issues such as further cytoreductive surgery and the use of carboplatin desensitizing agents are of interest, but are not a focus of the present report. A sentence regarding future research in these areas was added.

The present report reflects the integration of the feedback obtained through the external review process with the final approval given by the [rap]{.smallcaps} and the Gynecology Cancer [dsg]{.smallcaps}. Updates of the report will be issued as new evidence informing the question of interest emerges.

9. CONFLICT OF INTEREST
=======================
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###### 

Literature search results and selected trial characteristics

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                 Treatment regimen      Platinum-sensitive patients (%)                                                                                                                                                  
  ------------------------------------------------------------------------------------- ----- ------------------------------------------------------------------ ---------------------- --------------------------------- --------------------------------------------- ----------------------------------------------- ------------------------------------------------ ---------------------------------------------
  Pfisterer *et al.*, 2005[@b14-co14_5p195]                                             178   Carboplatin                                                        [auc]{.smallcaps}=5    1                                 6                                             0                                               100[a](#tfn1-co14_5p195){ref-type="table-fn"}    2

  [ncic ov]{.smallcaps}15                                                               178   Carboplatin/gemcitabine                                            [auc]{.smallcaps}=4\   1\                                6\                                            0                                               100 [a](#tfn1-co14_5p195){ref-type="table-fn"}   2
                                                                                                                                                                 1000 mg/m^2^           1+8                               6                                                                                                                                              

  Gonzalez--Martin *et al.*, 2005 [@b15-co14_5p195]                                     40    Carboplatin                                                        [auc]{.smallcaps}=5    1                                 6--9                                          0                                               100 [a](#tfn1-co14_5p195){ref-type="table-fn"}   2--3

  [geico]{.smallcaps}                                                                   41    Carboplatin/paclitaxel                                             [auc]{.smallcaps}=5\   1\                                6--9\                                         0                                               100[a](#tfn1-co14_5p195){ref-type="table-fn"}    2--3
                                                                                                                                                                 175 mg/m^2^            1                                 6--9                                                                                                                                           

  Buda *et al.*, 2004[@b16-co14_5p195]                                                  106   Paclitaxel                                                         175 mg/m^2^            1                                 4--6                                          75                                              25                                               2

  [gono]{.smallcaps}/[ior]{.smallcaps}                                                  106   Paclitaxel/epirubicin                                              175 mg/m^2^\           1\                                4--6\                                         73                                              27                                               2
                                                                                                                                                                 80 mg/m^2^             1                                 4--6                                                                                                                                           

  Gordon *et al.*, 2004[@b17-co14_5p195]                                                239   Pegylated doxorubicin                                              50 mg/m^2^             1                                 12                                            54                                              46                                               2

  Doxil 30-49                                                                           235   topotecan                                                          1.5 mg/m^2^            1--5                              12                                            53                                              47                                               2

  ten Bokkel Huinink *et al.*, 2004[@b18-co14_5p195]                                    112   Paclitaxel                                                         175 mg/m^2^            1                                 12                                            52                                              48                                               2

  [itsg]{.smallcaps}                                                                    114   Topotecan                                                          1.5 mg/m^2^            1--5                              12                                            54                                              46                                               2

  Meier *et al.*, 2004 [@b16-co14_5p195],[b](#tfn2-co14_5p195){ref-type="table-fn"}     179   Treosulfan                                                         7.0 g/m^2^             [nr]{.smallcaps}                  [nr]{.smallcaps}                              36                                              64                                               2--3

  [ago]{.smallcaps}                                                                     178   Topotecan                                                          1.5 mg/m^2^            1--5                              [nr]{.smallcaps}                              34                                              66                                               2--3

  Parmar *et al.*, 2003 [@b20-co14_5p195]                                               410   Carboplatin[c](#tfn3-co14_5p195){ref-type="table-fn"}              [auc]{.smallcaps}≥5    1                                 6--8                                          0                                               100[a](#tfn1-co14_5p195){ref-type="table-fn"}    2[d](#tfn4-co14_5p195){ref-type="table-fn"}

  [icon]{.smallcaps}4/[ago]{.smallcaps}                                                 392   Carboplatin/paclitaxel[c](#tfn3-co14_5p195){ref-type="table-fn"}   [auc]{.smallcaps}≥5\   1\                                6--8\                                         0                                               100[a](#tfn1-co14_5p195){ref-type="table-fn"}    2[d](#tfn4-co14_5p195){ref-type="table-fn"}
                                                                                                                                                                 ≥175 mg/m^2^           1                                 6--8                                                                                                                                           

  O'Byrne *et al.*, 2002 [@b21-co14_5p195],[b](#tfn2-co14_5p195){ref-type="table-fn"}   107   Pegylated doxorubicin                                              50 mg/m^2^             1                                 [nr]{.smallcaps}                              60                                              40                                               2

                                                                                        107   Paclitaxel                                                         175 mg/m^2^            1                                 [nr]{.smallcaps}                              63                                              37                                               2

  Cantu *et al.*, 2002[@b22-co14_5p195]                                                 50    Paclitaxel                                                         175 mg/m^2^            1                                 ≥6                                            0                                               100[e](#tfn5-co14_5p195){ref-type="table-fn"}    2

                                                                                        47    Cyclophosphamide/doxorubicin/cisplatin                             500 mg/m^2^\           1\                                ≥6\                                           0                                               100[e](#tfn5-co14_5p195){ref-type="table-fn"}    2
                                                                                                                                                                 50 mg/m^2^\            1\                                ≥6\                                                                                                                                            
                                                                                                                                                                 50 mg/m^2^             1                                 ≥6                                                                                                                                             

  Bolis *et al.*, 2001[@b23-co14_5p195]                                                 95    Carboplatin                                                        300 mg/m^2^            1                                 5                                             0                                               100                                              2

                                                                                        95    Carboplatin/epirubicin                                             300 mg/m^2^\           1\                                5\                                            0                                               100                                              2
                                                                                                                                                                 120 mg/m^2^            1                                 5                                                                                                                                              

  Piccart *et al.*, 2000[@b24-co14_5p195]                                               41    Paclitaxel                                                         175 mg/m^2^            1                                 6[f](#tfn6-co14_5p195){ref-type="table-fn"}   76                                              24                                               2--3

                                                                                        45    Oxaliplatin                                                        130 mg/m^2^            1                                 4[f](#tfn6-co14_5p195){ref-type="table-fn"}   71                                              29                                               2--3

  Torri *et al.*, 2000[@b25-co14_5p195],[b](#tfn2-co14_5p195){ref-type="table-fn"}      116   Paclitaxel                                                         175 mg/m^2^            1                                 4--6                                          ≥50[g](#tfn7-co14_5p195){ref-type="table-fn"}   ≤50[g](#tfn7-co14_5p195){ref-type="table-fn"}    2

                                                                                        118   Paclitaxel/doxorubicin                                             175 mg/m^2^\           1\                                4--6\                                         ≥50[g](#tfn7-co14_5p195){ref-type="table-fn"}   ≤50[g](#tfn7-co14_5p195){ref-type="table-fn"}    2
                                                                                                                                                                 80 mg/m^2^             1                                 4--6                                                                                                                                           

  Bolis *et al.*, 1999[@b26-co14_5p195]                                                 41    Paclitaxel                                                         175 mg/m^2^            1                                 5                                             100                                             0                                                2

                                                                                        40    Paclitaxel/epirubicin                                              150 mg/m^2^\           1\                                5\                                            100                                             0                                                2
                                                                                                                                                                 120 mg/m^2^            1                                 5                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Approximately 60% of patients were platinum-sensitive beyond 12 months.

Abstract data from conference proceedings.

The authors reported that 24% of patients received chemotherapy other than carboplatin or paclitaxel and carboplatin.

Among these patients, 8% received third- or greater-line chemotherapy.

In this trial, 100% of patients were platinum-sensitive beyond 12 months.

Actual median number of cycles delivered.

Median time from the end of first-line chemotherapy to trial randomization was 5 months, with a range of 3--12 months.

[ct]{.smallcaps} = chemotherapy; [ncic ov]{.smallcaps}15 = National Cancer Institute of Canada [ov]{.smallcaps}15 trial; [auc]{.smallcaps} = area under curve; [geico]{.smallcaps} = Grupo Espanol de Investigacion en Cancer de Ovario; [gono]{.smallcaps}/[ior]{.smallcaps} = Gruppo Oncologico Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; [itsg]{.smallcaps} = International Topotecan Study Group; [ago]{.smallcaps} = Arbeitsgemeinschaft Gynaekologische Onkologie.

###### 

Response rates and survival outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                        Response and survival outcomes[a](#tfn9-co14_5p195){ref-type="table-fn"}                                                                                                   
  ---------------------------------------------------- ----- -------------------------------------------------------------------- ----- -------------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------
  Pfisterer *et al.*, 2005[@b14-co14_5p195]            178   Carboplatin                                                          100   6                                                                          31                                              6                                               17

  [ncic ov]{.smallcaps}15                              178   Carboplatin/ gemcitabine                                             100   15\                                                                        47                                              9\                                              18
                                                                                                                                        ***p*\<0.01**                                                                                                              ***p*\<0.01**\                                  
                                                                                                                                                                                                                                                                   **[hr]{.smallcaps}=0.72**\                      
                                                                                                                                                                                                                                                                   **(0.58--0.90)**                                

  Gonzalez--Martin *et al.*, 2005[@b15-co14_5p195]     40    Carboplatin                                                          100   20                                                                         50                                              8                                               17

  [geico]{.smallcaps}                                  41    Carboplatin/ paclitaxel                                              100   27                                                                         76\                                             11\                                             Not reached\
                                                                                                                                                                                                                   ***p*=0.02**                                    ***p*=0.02**\                                   ***p*=0.002**\
                                                                                                                                                                                                                                                                   **[hr]{.smallcaps}=0.54**\                      **[hr]{.smallcaps}=0.31**\
                                                                                                                                                                                                                                                                   **(0.32--0.92)**                                **(0.14--0.68)**

  Buda *et al.*, 2004[@b16-co14_5p195]                 106   Paclitaxel                                                           25    20[b](#tfn10-co14_5p195){ref-type="table-fn"}                              47[b](#tfn10-co14_5p195){ref-type="table-fn"}   6                                               14

  [gono]{.smallcaps}/[ior]{.smallcaps}                 106   Paclitaxel/ epirubicin                                               27    15[b](#tfn10-co14_5p195){ref-type="table-fn"}                              37[b](#tfn10-co14_5p195){ref-type="table-fn"}   6                                               12

  Gordon *et al.*, 2004[@b17-co14_5p195] Doxil 30-49   239   Pegylated doxorubicin                                                46    4                                                                          20                                              4                                               15

                                                       235   Topotecan                                                            47    5                                                                          17                                              4                                               13\
                                                                                                                                                                                                                                                                                                                   ***p*=0.038**\
                                                                                                                                                                                                                                                                                                                   **[hr]{.smallcaps}=1.23**\
                                                                                                                                                                                                                                                                                                                   **(1.01--1.50)**

  ten Bokkel Huinink *et al.*, 2004[@b18-co14_5p195]   114   Paclitaxel                                                           48    3                                                                          13                                              3                                               12

  [itsg]{.smallcaps}                                   112   Topotecan                                                            46    5                                                                          21                                              4                                               15

  Meier *et al.*, 2004[@b19-co14_5p195]                179   Treosulfan                                                           64    [nr]{.smallcaps}                                                           [nr]{.smallcaps}                                3                                               [nr]{.smallcaps}

  [ago]{.smallcaps}                                    178   Topotecan                                                            66    [nr]{.smallcaps}                                                           [nr]{.smallcaps}                                5\                                              [nr]{.smallcaps}
                                                                                                                                                                                                                                                                   ***p*\<0.001**                                  

  Parmar *et al.*, 2003[@b20-co14_5p195]               410   Carboplatin[c](#tfn11-co14_5p195){ref-type="table-fn"}               100   [nr]{.smallcaps}                                                           54[b](#tfn10-co14_5p195){ref-type="table-fn"}   9                                               24

  [icon]{.smallcaps}4/[ago]{.smallcaps}                392   Carboplatin/ paclitaxel[c](#tfn11-co14_5p195){ref-type="table-fn"}   100   [nr]{.smallcaps}                                                           66[b](#tfn10-co14_5p195){ref-type="table-fn"}   12\                                             29\
                                                                                                                                                                                                                                                                   ***p*=0.0004**\                                 ***p*=0.02**\
                                                                                                                                                                                                                                                                   **[hr]{.smallcaps}=0.76**\                      **[hr]{.smallcaps}=0.82**\
                                                                                                                                                                                                                                                                   **(0.66--0.89)**                                **(0.69--0.97)**

  O'Byrne *et al.*, 2002[@b21-co14_5p195]              107   Pegylated doxorubicin                                                40    2                                                                          19                                              4                                               11

                                                       107   Paclitaxel                                                           37    6                                                                          23                                              5                                               13

  Cantu *et al.*, 2002[@b22-co14_5p195]                50    Paclitaxel                                                           100   17                                                                         45                                              9                                               26

                                                       47    [cap]{.smallcaps}                                                    100   30                                                                         55                                              16\                                             35\
                                                                                                                                                                                                                                                                   ***p*=0.038**\                                  ***p*=0.043**\
                                                                                                                                                                                                                                                                   **[hr]{.smallcaps}=0.60**\                      **[hr]{.smallcaps}=0.58**\
                                                                                                                                                                                                                                                                   **(0.37--0.97)**                                **(0.34--0.98)**

  Bolis *et al.*, 2001[@b23-co14_5p195]                95    Carboplatin                                                          100   35                                                                         55                                              \~15                                            \~23

                                                       95    Carboplatin/ epirubicin                                              100   30                                                                         58                                              \~18                                            \~28

  Piccart *et al.*, 2000[@b24-co14_5p195]              41    Paclitaxel                                                           24    0                                                                          17                                              3                                               9

                                                       45    Oxaliplatin                                                          29    0                                                                          16                                              3                                               10

  Torri *et al.*, 2000[@b25-co14_5p195]                116   Paclitaxel                                                           ≤50   [nr]{.smallcaps}                                                           54                                              8                                               14

                                                       118   Paclitaxel/ doxorubicin                                              ≤50   [nr]{.smallcaps}                                                           52                                              7                                               12

  Bolis *et al.*, 1999[@b26-co14_5p195]                41    Paclitaxel                                                           0     7                                                                          17                                              6[d](#tfn12-co14_5p195){ref-type="table-fn"}    \~9

                                                       40    Paclitaxel/ epirubicin                                               0     13                                                                         34                                              10[d](#tfn12-co14_5p195){ref-type="table-fn"}   \~14
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are rounded and only statistically significant differences between treatment groups are shown in boldface.

Based on evaluable patients.

The authors reported that 24% of patients received chemotherapy other than carboplatin or paclitaxel and carboplatin.

Median duration of response.

[cr]{.smallcaps} = complete response; [or]{.smallcaps} = objective response; [pr]{.smallcaps} = partial response; [pfs]{.smallcaps} = progression-free survival; [ncic ov]{.smallcaps}15 = National Cancer Institute of Canada [ov]{.smallcaps}15 trial; [hr]{.smallcaps} = hazard ratio; [geico]{.smallcaps} = Grupo Espanol de Investigacion en Cancer de Ovario; [gono]{.smallcaps}/[ior]{.smallcaps} = Gruppo Oncologico Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; [itsg]{.smallcaps} = International Topotecan Study Group; [ago]{.smallcaps} = Arbeitsgemeinschaft Gynaekologische Onkologie; [icon]{.smallcaps} = International Collaborative Ovarian Neoplasm Group; [nr]{.smallcaps} = not reported; [cap]{.smallcaps} = cyclophosphamide/doxorubicin/cisplatin; \~ = approximate values extracted from survival curves.

###### 

Patients with grade 3 or 4 adverse events during chemotherapy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        Adverse events (%)                                                                                                                                                                                                                                                                                                                                                                                  
  ---------------------------------------------------- ----- -------------------------- ----------------------------------------------- ----------------------------------------------- ------------------ ------------------ ------------------------------------------------ ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------------------------------------------------------------ ------------------------------------------------
  Pfisterer *et al.*, 2005[@b14-co14_5p195]            178   Carboplatin                8                                               [nr]{.smallcaps}                                12                 12                 2                                                2                                               0                                               [nr]{.smallcaps}                                5                                                            2[a](#tfn14-co14_5p195){ref-type="table-fn"}

  [ncic ov]{.smallcaps}15                              178   Carboplatin/ gemcitabine   27\                                             [nr]{.smallcaps}                                70\                35\                4                                                3                                               2                                               [nr]{.smallcaps}                                5                                                            14[a](#tfn14-co14_5p195){ref-type="table-fn"}\
                                                                                        ***p*\<0.01**                                                                                   ***p*\<0.01**      ***p*\<0.01**                                                                                                                                                                                                                                                                    ***p*\<0.01**

  Gonzalez--Martin *et al.*, 2005[@b15-co14_5p195]     40    Carboplatin                15                                              3                                               10                 13                 0                                                10                                              3[b](#tfn15-co14_5p195){ref-type="table-fn"}    8[b](#tfn15-co14_5p195){ref-type="table-fn"}    0[b](#tfn15-co14_5p195){ref-type="table-fn"}                 18[b](#tfn15-co14_5p195){ref-type="table-fn"}

  [geico]{.smallcaps}                                  38    Carboplatin/ paclitaxel    5                                               5                                               18                 3                  0                                                3                                               3[b](#tfn15-co14_5p195){ref-type="table-fn"}    8[b](#tfn15-co14_5p195){ref-type="table-fn"}    24[b](#tfn15-co14_5p195){ref-type="table-fn"}\               87[b](#tfn15-co14_5p195){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                               ***p*\<0.009**                                               ***p*=0.001**

  Buda *et al.*, 2004[@b16-co14_5p195]                 99    Paclitaxel                 5                                               9                                               18                 1                  6                                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                14[c](#tfn16-co14_5p195){ref-type="table-fn"}   69[d](#tfn17-co14_5p195){ref-type="table-fn"}                

  [gono/ior]{.smallcaps}                               99    Paclitaxel/ epirubicin     3                                               19                                              37\                1                  11                                               [nr]{.smallcaps}                                [nr]{.smallcaps}                                12[c](#tfn16-co14_5p195){ref-type="table-fn"}   62[d](#tfn17-co14_5p195){ref-type="table-fn"}                
                                                                                                                                                                                        ***p*=0.01**                                                                                                                                                                                                                                                                                        

  Gordon *et al.*, 2004[@b17-co14_5p195]               239   Pegylated doxorubicin      5                                               10                                              12                 1                  [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                             16

  Doxil 30-49                                          235   Topotecan                  28\                                             50\                                             77\                34\                [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                             49\
                                                                                        ***p*\<0.001**                                  ***p*\<0.001**                                  ***p*\<0.001**     ***p*\<0.001**                                                                                                                                                                                                                                                                   ***p*=0.007**

  ten Bokkel Huinink *et al.*, 2004[@b18-co14_5p195]   114   Paclitaxel                 6                                               21                                              52                 3                  2                                                3                                               1[d](#tfn17-co14_5p195){ref-type="table-fn"}    0[d](#tfn17-co14_5p195){ref-type="table-fn"}    16                                                           93

  [itsg]{.smallcaps}                                   112   Topotecan                  41                                              85                                              95\                50\                10                                               10                                              6[d](#tfn17-co14_5p195){ref-type="table-fn"}    5[d](#tfn17-co14_5p195){ref-type="table-fn"}    1                                                            76
                                                                                                                                                                                        ***p*\<0.01**      ***p*\<0.01**                                                                                                                                                                                                                                                                    

  Meier *et al.*, 2004[@b19-co14_5p195]                179   Treosulfan                 1                                               [nr]{.smallcaps}                                5                  2                  [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                             [nr]{.smallcaps}

  [ago]{.smallcaps}                                    178   Topotecan                  4                                               [nr]{.smallcaps}                                47                 7                  [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                             [nr]{.smallcaps}

  Parmar *et al.*, 2003[@b20-co14_5p195]               410   Carboplatin                46[e](#tfn18-co14_5p195){ref-type="table-fn"}   40[b](#tfn15-co14_5p195){ref-type="table-fn"}   [nr]{.smallcaps}   [nr]{.smallcaps}   1[b](#tfn15-co14_5p195){ref-type="table-fn"}     25[b](#tfn15-co14_5p195){ref-type="table-fn"}   40[b](#tfn15-co14_5p195){ref-type="table-fn"}                                                                                                                

  [icon]{.smallcaps}4/[ago]{.smallcaps}                392   Carboplatin/ paclitaxel    29[e](#tfn18-co14_5p195){ref-type="table-fn"}   35[b](#tfn15-co14_5p195){ref-type="table-fn"}   [nr]{.smallcaps}   [nr]{.smallcaps}   20[b](#tfn15-co14_5p195){ref-type="table-fn"}    86[b](#tfn15-co14_5p195){ref-type="table-fn"}   35[b](#tfn15-co14_5p195){ref-type="table-fn"}                                                                                                                

  O'Byrne *et al.*, 2002[@b21-co14_5p195]              107   Pegylated doxorubicin      2                                               6                                               7                  [nr]{.smallcaps}   7                                                9                                               [nr]{.smallcaps}                                [nr]{.smallcaps}                                13[f](#tfn19-co14_5p195){ref-type="table-fn"}                44

                                                       107   Paclitaxel                 4                                               8                                               13                 [nr]{.smallcaps}   2                                                2                                               [nr]{.smallcaps}                                [nr]{.smallcaps}                                42[f](#tfn19-co14_5p195){ref-type="table-fn"}\               88\
                                                                                                                                                                                                                                                                                                                                                                                                                               ***p*=0.002**                                                ***p*=0.002**

  Cantu *et al.*, 2002[@b22-co14_5p195]                47    Paclitaxel                 [nr]{.smallcaps}                                4                                               13                 0                  17[c](#tfn16-co14_5p195){ref-type="table-fn"}    [nr]{.smallcaps}                                [nr]{.smallcaps}                                11                                              87                                                           

                                                       47    [cap]{.smallcaps}          [nr]{.smallcaps}                                34\                                             36\                13\                51[c](#tfn16-co14_5p195){ref-type="table-fn"}\   [nr]{.smallcaps}                                [nr]{.smallcaps}                                6\                                              60\                                                          
                                                                                                                                        ***p*=0.001**                                   ***p*=0.009**      ***p*=0.012**      ***p*=0.004**                                                                                                                                    ***p*=0.002**                                   ***p*=0.01**                                                 

  Bolis *et al.*, 2001[@b23-co14_5p195]                95    Carboplatin                10                                              13                                              [nr]{.smallcaps}   20                 3                                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                5[g](#tfn20-co14_5p195){ref-type="table-fn"}                 

                                                       95    Carboplatin/ epirubicin    25\                                             53\                                             [nr]{.smallcaps}   64\                13\                                              [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                88[g](#tfn20-co14_5p195){ref-type="table-fn"}***p*\<0.01**   
                                                                                        ***p*\<0.05**                                   ***p*\<0.05**                                                      ***p*\<0.05**      ***p*\<0.05**                                                                                                                                                                                                                                                 

  Piccart *et al.*, 2000[@b24-co14_5p195]              41    Paclitaxel                 2                                               [nr]{.smallcaps}                                22                 0                  2                                                2                                               0[g](#tfn20-co14_5p195){ref-type="table-fn"}    [nr]{.smallcaps}                                7[g](#tfn20-co14_5p195){ref-type="table-fn"}                 [nr]{.smallcaps}

                                                       45    Oxaliplatin                2                                               [nr]{.smallcaps}                                0                  4                  4                                                7                                               4[g](#tfn20-co14_5p195){ref-type="table-fn"}    [nr]{.smallcaps}                                9[g](#tfn20-co14_5p195){ref-type="table-fn"}                 [nr]{.smallcaps}

  Torri *et al.*, 2000[@b25-co14_5p195]                116   Paclitaxel                 [nr]{.smallcaps}                                7                                               [nr]{.smallcaps}   [nr]{.smallcaps}   [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                19[c](#tfn16-co14_5p195){ref-type="table-fn"}                [nr]{.smallcaps}

                                                       118   Paclitaxel/ doxorubicin    [nr]{.smallcaps}                                24\                                             [nr]{.smallcaps}   [nr]{.smallcaps}   [nr]{.smallcaps}                                 [nr]{.smallcaps}                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                19[c](#tfn16-co14_5p195){ref-type="table-fn"}                [nr]{.smallcaps}
                                                                                                                                        ***p*\<0.05**                                                                                                                                                                                                                                                                                                                                       

  Bolis *et al.*, 1999[@b26-co14_5p195]                41    Paclitaxel                 12                                              24                                              [nr]{.smallcaps}   2                  2                                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                15[c](#tfn16-co14_5p195){ref-type="table-fn"}   100                                                          

                                                       40    Paclitaxel/ epirubicin     30\                                             45\                                             [nr]{.smallcaps}   25\                8                                                [nr]{.smallcaps}                                [nr]{.smallcaps}                                5[c](#tfn16-co14_5p195){ref-type="table-fn"}    100                                                          
                                                                                        ***p*=0.04**                                    ***p*=0.05**                                                       ***p*=0.003**                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Grade 2 toxicity.

Grades 2--4 toxicity combined.

Grades 2--3 toxicity combined.

Grades 3--4 toxicity combined.

Hematologic toxicity leading to treatment modification or interruption.

Paresthesia.

Grade 3 toxicity.

[ncic ov]{.smallcaps}15 = National Cancer Institute of Canada [ov]{.smallcaps}15 trial; [nr]{.smallcaps} = not reported; [geico]{.smallcaps} = Grupo Espanol de Investigacion en Cancer de Ovario; [gono]{.smallcaps}/[ior]{.smallcaps} = Gruppo Oncologico Nord Ovest/Istituto Oncologico Romagnolo; Doxil 30-49 = Doxil Study 30-49; [itsg]{.smallcaps} = International Topotecan Study Group; [ago]{.smallcaps} = Arbeitsgemeinschaft Gynaekologische Onkologie; [icon]{.smallcaps} = International Collaborative Ovarian Neoplasm Group; [cap]{.smallcaps} = cyclophosphamide/doxorubicin/cisplatin.

###### 

Practitioner responses to eight items on the practitioner feedback survey

  Item                                                                                                                              Strongly agree or agree   Responses \[*n* (%)\] Neither agree nor disagree   Strongly disagree or disagree
  --------------------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------- -------------------------------
  The rationale for developing a clinical practice guideline, as stated in the "Choice of Topic" section of the report, is clear.   19 (90.5)                 1 (4.8)                                            1 (4.8)
  There is a need for a clinical practice guideline on this topic.                                                                  19 (86.4)                 1 (4.5)                                            2 (9.1)
  The literature search is relevant and complete.                                                                                   19 (90.5)                 1 (4.8)                                            1 (4.8)
  The results of the trials described in the report are interpreted according to my understanding of the data.                      20 (90.9)                 1 (4.5)                                            1 (4.5)
  The draft recommendations in this report are clear.                                                                               20 (90.9)                 1 (4.5)                                            1 (4.5)
  I agree with the draft recommendations as stated.                                                                                 20 (90.9)                 0 (0.0)                                            2 (9.1)
  This report should be approved as a practice guideline.                                                                           17 (81.0)                 2 (9.5)                                            2 (9.5)
                                                                                                                                                                                                                 
                                                                                                                                    Very likely or likely     Unsure                                             Not at all likely or unlikely
                                                                                                                                                                                                                 
  If this report were to become a practice guideline, how likely would you be to make use of it in your own practice?               20 (95.3)                 0 (0.0)                                            1 (4.8)

[^1]: Please see the Web site of Cancer Care Ontario's Program in Evidence-Based Care ([www.cancercare.on.ca/access_PEBC.htm](www.cancercare.on.ca/access_PEBC.htm)) for a complete list of current Gynecology Cancer Disease Site Group members.
